ACM
MDGL icon

Atika Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Atika Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-40,000
Closed -$3.45M – 82
2019
Q3 		$3.45M Buy
40,000
+23,000
+135% +$2.16M 0.73% 50
2019
Q2 		$1.78M Sell
17,000
-10,000
-37% -$1.07M 0.35% 72
2019
Q1 		$754K Buy
27,000
+7,000
+35% +$870K 0.15% 71
2018
Q4 		$2.25M Buy
+20,000
New +$3.1M 0.66% 56

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's MDGL Position: Q1 2026 in Review

Atika Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 34,000 shares — an estimated $19.8M sold.

Atika Capital Management first reported a position in MDGL in Q1 2018 and held it in 4 quarters. The position peaked at $19.8M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Atika Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Atika Capital Management sold 34,000 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $19.8M.
  • Atika Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Atika Capital Management's Madrigal Pharmaceuticals position peaked at $19.8M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.